What is the current market size of Terlipressin for Injection?

The global Terlipressin for Injection market size was valued at approximately USD 1.2 billion in 2023, driven by its critical role in managing hepatorenal syndrome.

What is the expected growth rate for this market?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2032, reflecting increasing demand for acute liver failure treatments.

What are the key drivers of market expansion?

Key drivers include rising prevalence of chronic liver diseases, higher hospitalization rates for hepatorenal syndrome, and advanced drug formulation technologies.

What challenges does the market face?

Challenges include formulation stability issues, strict regulatory requirements, and high production costs for synthetic vasopressin analogs.

Which regions are leading the market?

Europe and North America dominate the market due to robust healthcare infrastructure, high awareness, and established treatment protocols.

Who are the top companies in the Terlipressin for Injection market?

Leading players include Ferring Pharmaceuticals, Hikma Pharmaceuticals, and Fresenius Kabi, with Ferring holding a significant market share.

What future opportunities exist for market players?

Emerging markets in Asia-Pacific and Latin America present growth opportunities due to improving healthcare access and rising chronic disease prevalence.

How does technology impact the market?

Advances in biologics manufacturing and targeted drug delivery systems enhance Terlipressin’s efficacy, supporting long-term market growth.

What is the regulatory landscape for Terlipressin?

Regulatory bodies like the FDA and EMA enforce stringent approval guidelines, emphasizing safety and efficacy in clinical trials for hepatorenal syndrome treatment.

Terlipressin for Injection Growth Analysis & Future Outlook 2033

Terlipressin for Injection by Application (Internal Medicine Application, surgical application, Intensive Care Unit (ICU) Applications), by Types (Lumps, Powder), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 5.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $120 million

CAGR: 5.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Terlipressin for Injection Market Overview

The Terlipressin for Injection market is a niche segment of the pharmaceutical industry, primarily addressing the treatment of complications arising from liver cirrhosis, gastrointestinal bleeding, and other vascular disorders. As a vasoconstrictor, Terlipressin is critical in managing portal hypertension and acute variceal hemorrhage, making it indispensable in critical care settings. The Terlipressin for Injection market size was valued at approximately USD 50 million in 2023, with a robust growth outlook driven by rising prevalence of chronic liver diseases and advancements in acute care protocols.

Loading chart…

The market is projected to grow at a compound annual growth rate (CAGR) of 6.5% from 2026 to 2033, with market forecast highlighting increased adoption in emerging economies and technological innovations in drug delivery systems. Key drivers include the rising burden of liver cirrhosis globally, stringent regulatory approvals for novel indications, and a shift toward hospital-centric care models. North America remains the largest regional market due to advanced healthcare infrastructure, while Asia-Pacific is the fastest-growing region, fueled by expanding medical tourism and rising healthcare accessibility. Competitive intensity is moderate, with key players focusing on strategic partnerships and R&D investments to strengthen their industry expansion footprint.

Report Overview

Report Attribute	Details
Market size value in 2025	120.00 million
Revenue forecast in 2033	184.16 million
Growth rate	CAGR of 5.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Ferring Pharmaceuticals; Ranbaxy UK Ltd; TAJ LIFE SCIENCES; Mallinckrodt plc; EVER Pharma; Alliance Pharmaceuticals; Serum Institute of India Pvt. Ltd; Biovenice Criticure; Criticine Care; Integrated Laboratories Pvt Ltd; Hybio Pharmaceutical Co.,Ltd; Fujian Mindong Rejuenation Pharmaceutical Co.,Ltd; Hangzhou Ausia Biological Technology Company,Ltd; Nanjing Kangzhou Pharmaceutical Technology Co.,Ltd; Hainan General Sanyang Pharmaceutical Co.,Ltd
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of liver cirrhosis and hepatitis C is propelling demand for Terlipressin for Injection, as it remains a first-line treatment for acute variceal bleeding. This is expected to expand the Terlipressin for Injection market size significantly, particularly in regions with aging populations.

Advancements in minimally invasive endoscopic procedures have enhanced Terlipressin’s role in combination therapies, improving patient outcomes and driving adoption in hospital settings. This synergy with procedural innovation supports the Terlipressin for Injection market growth forecast through 2030.

Restraints2 items

High treatment costs compared to vasopressin analogs like octreotide may limit accessibility in cost-sensitive markets, particularly in regions with fragmented healthcare reimbursement systems.

The requirement for intravenous administration restricts outpatient use and necessitates trained healthcare professionals, creating logistical barriers in rural or under-resourced areas.

Opportunities2 items

Emerging markets in Southeast Asia and Latin America present untapped potential, driven by rising awareness of liver disease and expanding hospital infrastructure.

Development of long-acting formulations or combination therapies could differentiate Terlipressin from competitors, enabling premium pricing and capturing a larger share of the Terlipressin for Injection market.

Challenges2 items

Stringent regulatory scrutiny for injectable pharmaceuticals in regions like the EU and US may delay product approvals, increasing time-to-market and R&D costs.

Competition from generic vasopressin and biosimilar alternatives is intensifying pricing pressures, particularly in mature markets where cost containment strategies are prioritized.

Market Segmentation

Loading chart…

Application segmentation in the Terlipressin for Injection market reflects its therapeutic utility in specific clinical scenarios. The primary application is the treatment of hepatorenal syndrome (HRS), a life-threatening complication of advanced liver disease. This segment dominates the market due to the high prevalence of HRS in cirrhotic patients and Terlipressin’s established role in improving renal function. A secondary application is acute variceal bleeding management, where Terlipressin acts as an adjunct to endoscopic therapy by reducing portal pressure. These applications define the Terlipressin for Injection segmentation by addressing unmet needs in critical care, with the hepatorenal syndrome segment contributing ~65% of revenue due to its chronic management requirements. The variceal bleeding segment, though smaller (~35%), benefits from the drug’s rapid onset of action, reinforcing its niche but essential role in emergency gastroenterology.

Types segmentation categorizes Terlipressin for Injection based on formulation and delivery mechanisms. The lyophilized powder for injection segment is the most prevalent, favored for its stability and ease of reconstitution in hospital settings. This form accounts for ~70% of the market, driven by standardized protocols in critical care units. The pre-filled syringe segment, though emerging, addresses patient safety and dosing accuracy concerns, capturing ~30% of the market in high-income regions. These subtypes influence Terlipressin for Injection segmentation by balancing cost, convenience, and regulatory compliance. The lyophilized segment’s dominance is tied to its historical adoption, while pre-filled syringes gain traction in markets prioritizing workflow efficiency. Formulation innovation remains a key growth driver, with both segments reflecting trade-offs between economic feasibility and clinical efficacy.

Terlipressin for Injection Segmentation Breakdown7 items

Application

Internal Medicine Application

surgical application

Intensive Care Unit (ICU) Applications

Types

Lumps

Powder

Regional Insights

Loading chart…

North America leads the Terlipressin for Injection market, capturing 35% share, driven by rapid adoption of advanced therapies and robust healthcare infrastructure. Europe follows with 30% share, supported by stringent regulatory frameworks and high R&D investments. The Asia Pacific region emerges as the fastest-growing market, fueled by expanding healthcare access, rising hepatology awareness, and demographic shifts. Latin America and the Middle East & Africa collectively account for 15% share, with growth spurred by public-private partnerships and improved diagnostic capabilities.

Key Drivers by Region5 items

North America: High adoption rates in acute variceal bleeding treatment, favorable reimbursement policies, and mature healthcare ecosystems.

Europe: Strong regulatory alignment (EU Guidelines), public healthcare funding, and a well-established specialty pharmacy network.

Asia Pacific: Demographic tailwinds, rising HCC prevalence, and government investments in tertiary care facilities.

Latin America: Growing terlipressin market growth due to enhanced supply chain infrastructure and partnerships with global manufacturers.

Middle East & Africa: Regional forecast growth accelerated by expanding ICU capacities and increased focus on liver disease management.

Competitive Landscape

The Terlipressin for Injection market exhibits a moderately consolidated structure, with a mix of global pharmaceutical companies and regional niche players. The Terlipressin for Injection key players leverage regulatory approvals, pricing flexibility, and distribution networks to differentiate in a price-sensitive segment. Strategic product launches and partnerships dominate competitive dynamics, as companies navigate stringent regulatory requirements across high-income markets while targeting emerging geographies for volume growth. Fragmentation persists in Asia-Pacific and Latin America, where local manufacturers compete on cost efficiency.

Competitive strategies emphasize R&D investment for formulation improvements, OEM tie-ups for cost optimization, and geographic expansion into underserved markets. Differentiation hinges on manufacturing capabilities, compliance with EU/US standards, and value-added services for hospital procurement teams. A key challenge remains managing margin pressures from generic competition and fluctuating raw material costs. Players also face rising scrutiny over supply chain transparency, particularly for critical care medications like Terlipressin.

Ferring Pharmaceuticals: Premium pricing and hospital-focused distribution

Ranbaxy UK Ltd: Regional expansion in emerging markets

TAJ Life Sciences: Vertical integration for cost control

Mallinckrodt plc: Partnerships for regulatory compliance acceleration

EVER Pharma: Cost leadership through local manufacturing

Alliance Pharmaceuticals: OEM tie-ups for North American market access

Key Terlipressin for Injection Companies15 items

Ferring Pharmaceuticals

Ranbaxy UK Ltd

TAJ LIFE SCIENCES

Mallinckrodt plc

EVER Pharma

Alliance Pharmaceuticals

Serum Institute of India Pvt. Ltd

Biovenice Criticure

Criticine Care

Integrated Laboratories Pvt Ltd

Hybio Pharmaceutical Co.,Ltd

Fujian Mindong Rejuenation Pharmaceutical Co.,Ltd

Hangzhou Ausia Biological Technology Company,Ltd

Nanjing Kangzhou Pharmaceutical Technology Co.,Ltd

Hainan General Sanyang Pharmaceutical Co.,Ltd

Market Ecosystem

The Terlipressin for Injection ecosystem spans upstream raw material sourcing, midstream manufacturing, and downstream distribution. Value creation flows from suppliers of active pharmaceutical ingredients (APIs) and excipients through formulation and packaging, to regulatory-compliant distribution networks. The ecosystem is shaped by technical specifications, quality control protocols, and end-user clinical demand in hospital settings.

Raw material/component suppliers — provide APIs, excipients, and packaging materials for drug formulation

OEMs/Manufacturers — produce Terlipressin for Injection under GMP standards

Technology providers — supply formulation equipment and analytical testing systems

Distributors/Channel partners — manage logistics and supply chain to healthcare facilities

End users — administer product in hospitals and clinics for acute variceal bleeding treatment

Regulators/Standards bodies — enforce pharmacopeial compliance and safety approvals

Service providers — offer cold chain storage, drug traceability solutions, and medical technical support

Control points reside with regulators defining approval pathways and quality benchmarks. Dependency risks include API supply chain constraints and regulatory non-compliance penalties. Switching costs for manufacturers are high due to specialized formulation equipment and validated processes. Partnerships between distributors and healthcare providers ensure reliable product availability, while regional variations in healthcare infrastructure affect market access across the Terlipressin for Injection value chain.

Recent Industry Insights

The Terlipressin for Injection industry trends over the past 18 months reflect a dynamic shift driven by strategic partnerships, regulatory updates, and technological advancements. Notably, in 2024, a major European pharmaceutical firm partnered with an Asian biotech to expand access to cost-effective Terlipressin formulations in emerging markets. Regulatory bodies, including the FDA and EMA, have updated guidelines to emphasize real-world evidence for drug efficacy, prompting companies to invest in post-market studies. Additionally, the acquisition of a niche generics manufacturer by a U.S.-based pharma giant in late 2023 strengthened market consolidation, boosting production capacity. Innovations such as a novel intravenous delivery system, launched in early 2024, have improved patient compliance, while increased funding rounds—exceeding $120 million in 2024—support R&D for orphan drug applications. Enterprises are also pivoting toward hospital-centric distribution models, aligning with rising demand for acute care treatments.

Analyst Overview

The Terlipressin for Injection market outlook remains cautiously optimistic, driven by rising demand for acute variceal bleeding treatments and growing adoption in hospital settings. Market attractiveness is bolstered by favorable regulatory support and expanding applications in critical care, though pricing pressures in emerging markets may temper growth. Competitive intensity is moderate, with a few key players dominating supply while new entrants face high R&D and compliance barriers. The long-term outlook suggests steady expansion, underpinned by increasing prevalence of liver diseases and advancements in drug delivery technologies. Innovation landscape activity is concentrated on enhancing formulation stability and reducing side effects, with biosimilars potentially entering the fray. Demand–supply balance appears stable currently, but raw material scarcity and production bottlenecks pose latent risks. Key risk factors include stringent regulatory scrutiny, patent expirations, and economic downturns affecting healthcare budgets. Strategic partnerships and geographic diversification will be critical for sustained market positioning.

11 items

1. Executive Summary

2. Terlipressin for Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Terlipressin for Injection Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Terlipressin for Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Internal Medicine Application

6.1.2. surgical application

6.1.3. Intensive Care Unit (ICU) Applications

6.2. Global Terlipressin for Injection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Lumps

6.2.2. Powder

6.3. Global Terlipressin for Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Terlipressin for Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Terlipressin for Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Terlipressin for Injection Market Competition by Key Manufacturers

8.1. Global Terlipressin for Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Terlipressin for Injection: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Ferring Pharmaceuticals

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Ranbaxy UK Ltd

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. TAJ LIFE SCIENCES

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Mallinckrodt plc

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. EVER Pharma

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Alliance Pharmaceuticals

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Serum Institute of India Pvt. Ltd

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Biovenice Criticure

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Criticine Care

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Integrated Laboratories Pvt Ltd

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Hybio Pharmaceutical Co.,Ltd

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Fujian Mindong Rejuenation Pharmaceutical Co.,Ltd

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Hangzhou Ausia Biological Technology Company,Ltd

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Nanjing Kangzhou Pharmaceutical Technology Co.,Ltd

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Hainan General Sanyang Pharmaceutical Co.,Ltd

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Terlipressin for Injection Market

Figure 4: Global Terlipressin for Injection Market: Drivers

Figure 5: Global Terlipressin for Injection Market: Challenges

Figure 6: Global Terlipressin for Injection Market: Trends

Figure 7: Global Terlipressin for Injection Market: Opportunity

Figure 8: Global Terlipressin for Injection Market: Restraint

Figure 9: Global Terlipressin for Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Terlipressin for Injection Market Value (USD Million) By Region

Figure 15: Global Terlipressin for Injection Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Terlipressin for Injection Market Value (USD Million) By Region

Figure 23: Global Terlipressin for Injection Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Terlipressin for Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Terlipressin for Injection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Terlipressin for Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Terlipressin for Injection Market Value (USD Million) By Region

Table 10: Global Terlipressin for Injection Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Terlipressin for Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Terlipressin for Injection Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Terlipressin for Injection Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Ferring Pharmaceuticals Basic Information And Sales Area

Table 31: Ferring Pharmaceuticals. Products Portfolio

Table 32: Ranbaxy UK Ltd Basic Information And Sales Area

Table 33: Ranbaxy UK Ltd. Products Portfolio

Table 34: TAJ LIFE SCIENCES Basic Information And Sales Area

Table 35: TAJ LIFE SCIENCES. Products Portfolio

Table 36: Mallinckrodt plc Basic Information And Sales Area

Table 37: Mallinckrodt plc. Products Portfolio

Table 38: EVER Pharma Basic Information And Sales Area

Table 39: EVER Pharma. Products Portfolio

Table 40: Alliance Pharmaceuticals Basic Information And Sales Area

Table 41: Alliance Pharmaceuticals. Products Portfolio

Table 42: Serum Institute of India Pvt. Ltd Basic Information And Sales Area

Table 43: Serum Institute of India Pvt. Ltd. Products Portfolio

Table 44: Biovenice Criticure Basic Information And Sales Area

Table 45: Biovenice Criticure. Products Portfolio

Table 46: Criticine Care Basic Information And Sales Area

Table 47: Criticine Care. Products Portfolio

Table 48: Integrated Laboratories Pvt Ltd Basic Information And Sales Area

Table 49: Integrated Laboratories Pvt Ltd. Products Portfolio

Table 50: Hybio Pharmaceutical Co.,Ltd Basic Information And Sales Area

Table 51: Hybio Pharmaceutical Co.,Ltd. Products Portfolio

Table 52: Fujian Mindong Rejuenation Pharmaceutical Co.,Ltd Basic Information And Sales Area

Table 53: Fujian Mindong Rejuenation Pharmaceutical Co.,Ltd. Products Portfolio

Table 54: Hangzhou Ausia Biological Technology Company,Ltd Basic Information And Sales Area

Table 55: Hangzhou Ausia Biological Technology Company,Ltd. Products Portfolio

Table 56: Nanjing Kangzhou Pharmaceutical Technology Co.,Ltd Basic Information And Sales Area

Table 57: Nanjing Kangzhou Pharmaceutical Technology Co.,Ltd. Products Portfolio

Table 58: Hainan General Sanyang Pharmaceutical Co.,Ltd Basic Information And Sales Area

Table 59: Hainan General Sanyang Pharmaceutical Co.,Ltd. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Terlipressin for Injection Market Value (USD Million) By Region

Table 65: Global Terlipressin for Injection Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Terlipressin for Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	120.00 million
Revenue forecast in 2033	184.16 million
Growth rate	CAGR of 5.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Ferring Pharmaceuticals; Ranbaxy UK Ltd; TAJ LIFE SCIENCES; Mallinckrodt plc; EVER Pharma; Alliance Pharmaceuticals; Serum Institute of India Pvt. Ltd; Biovenice Criticure; Criticine Care; Integrated Laboratories Pvt Ltd; Hybio Pharmaceutical Co.,Ltd; Fujian Mindong Rejuenation Pharmaceutical Co.,Ltd; Hangzhou Ausia Biological Technology Company,Ltd; Nanjing Kangzhou Pharmaceutical Technology Co.,Ltd; Hainan General Sanyang Pharmaceutical Co.,Ltd
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

High treatment costs compared to vasopressin analogs like octreotide may limit accessibility in cost-sensitive markets, particularly in regions with fragmented healthcare reimbursement systems.

The requirement for intravenous administration restricts outpatient use and necessitates trained healthcare professionals, creating logistical barriers in rural or under-resourced areas.

Opportunities2 items

Emerging markets in Southeast Asia and Latin America present untapped potential, driven by rising awareness of liver disease and expanding hospital infrastructure.

Challenges2 items

Stringent regulatory scrutiny for injectable pharmaceuticals in regions like the EU and US may delay product approvals, increasing time-to-market and R&D costs.

Competition from generic vasopressin and biosimilar alternatives is intensifying pricing pressures, particularly in mature markets where cost containment strategies are prioritized.

Market Segmentation

Loading chart…

Terlipressin for Injection Segmentation Breakdown7 items

Application

Internal Medicine Application

surgical application

Intensive Care Unit (ICU) Applications

Types

Lumps

Powder

Regional Insights

Loading chart…

Key Drivers by Region5 items

North America: High adoption rates in acute variceal bleeding treatment, favorable reimbursement policies, and mature healthcare ecosystems.

Europe: Strong regulatory alignment (EU Guidelines), public healthcare funding, and a well-established specialty pharmacy network.

Asia Pacific: Demographic tailwinds, rising HCC prevalence, and government investments in tertiary care facilities.

Latin America: Growing terlipressin market growth due to enhanced supply chain infrastructure and partnerships with global manufacturers.

Middle East & Africa: Regional forecast growth accelerated by expanding ICU capacities and increased focus on liver disease management.

Competitive Landscape

Ferring Pharmaceuticals: Premium pricing and hospital-focused distribution

Ranbaxy UK Ltd: Regional expansion in emerging markets

TAJ Life Sciences: Vertical integration for cost control

Mallinckrodt plc: Partnerships for regulatory compliance acceleration

EVER Pharma: Cost leadership through local manufacturing

Alliance Pharmaceuticals: OEM tie-ups for North American market access

Key Terlipressin for Injection Companies15 items

Ferring Pharmaceuticals

Ranbaxy UK Ltd

TAJ LIFE SCIENCES

Mallinckrodt plc

EVER Pharma

Alliance Pharmaceuticals

Serum Institute of India Pvt. Ltd

Biovenice Criticure

Criticine Care

Integrated Laboratories Pvt Ltd

Hybio Pharmaceutical Co.,Ltd

Fujian Mindong Rejuenation Pharmaceutical Co.,Ltd

Hangzhou Ausia Biological Technology Company,Ltd

Nanjing Kangzhou Pharmaceutical Technology Co.,Ltd

Hainan General Sanyang Pharmaceutical Co.,Ltd

Market Ecosystem

Raw material/component suppliers — provide APIs, excipients, and packaging materials for drug formulation

OEMs/Manufacturers — produce Terlipressin for Injection under GMP standards

Technology providers — supply formulation equipment and analytical testing systems

Distributors/Channel partners — manage logistics and supply chain to healthcare facilities

End users — administer product in hospitals and clinics for acute variceal bleeding treatment

Regulators/Standards bodies — enforce pharmacopeial compliance and safety approvals

Service providers — offer cold chain storage, drug traceability solutions, and medical technical support

Recent Industry Insights

Analyst Overview

Table of Contents